RxDoctor Payments Data

Callie Hart

Physician Assistant · Mt Pleasant, MINPI 1104458942

Payments from drug & device makers

$8,175in general payments, 2019–2025

Across 445 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$964
  • Gilead$474
  • Lilly USA, LLC$387
  • Takeda Pharmaceuticals U.S.A., Inc.$349
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$8,08199%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,175 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$44,777
Medicare patients
227
Services billed
1,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide89$94,185
XifaxanRifaximin23$82,406
RinvoqUpadacitinib12$75,622
CreonLipase/Protease/Amylase14$54,014
Mesalamine64$38,606
Mesalamine DrMesalamine29$9,849
Lubiprostone26$8,885
PentasaMesalamine12$4,242
Pantoprazole Sodium150$4,031
Ursodiol22$3,930
Omeprazole215$3,319
Budesonide DrBudesonide23$2,633
Balsalazide Disodium15$2,294
Famotidine73$2,225
CholestyramineCholestyramine (With Sugar)12$2,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Rinvoq, Creon$1,791$223,821115 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,104$82,40623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Mt Pleasant

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →